Mondobiotech Holding AG Company presentation

More documents

Recommendations

Info

mondoBIOTECH’s IP Strategy Background • Our medicinal product candidates (MPCs) are already known peptides, whose properties and mechanisms of actions are described in a large number of publications (10’000 to 100’000 for each peptide) • Many of our MPCs have already been on the market for a different indication or were tested in humans for a different indication • Peptides with large amount of literature available constitute the universe for our Search&Match to find a valid match with one or more rare diseases. Such matches are further analyzed to become a robust MPC in our pipeline • Peptides with a larger number of information and studies available are the best candidates for a viable development strategy, where a fast track to market can be designed for our licensees, both for safety and efficacy profiles • Each of our MPCs is a product platform which can be re-directed for a variety of new indications, in rare diseases and potentially in non-rare diseases 30
mondoBIOTECH’s IP Strategy Two independent exclusivity rights PATENTS ORPHAN DRUGS • Protection worldwide via PCT • 20 years + 5 exclusivity from priority date • Substance protection, first or second medical use for the peptide in one or more diseases • Competence: Patent Offices • Granted in 5-6 years from the filing date • Application possible in 9 areas • 7 to 10 years exclusivity from Market Approval • Use of the peptide for a orphan disease • Protocol Assistance and other important development incentives • Competence: Central Regulatory Authorities • Granted in 60 to 90 days from applications 31
Page 1 and 2: Mondobiotech Holding AG Company pre
Page 3 and 4: mondoBIOTECH at a glance • Headqu
Page 5 and 6: Board of Directors Robert Edward Pa
Page 7 and 8: Our approach to drug discovery •
Page 9 and 10: Introduction to the Search&Match me
Page 11 and 12: The Model • Knowledge from litera
Page 13 and 14: The Search and Match Software Platf
Page 15 and 16: Match • Any path through the know
Page 17 and 18: Match - a multi-technique approach
Page 19 and 20: Bio-Mathematical Technology Platfor
Page 21 and 22: Match - Project DK-0112-01 21
Page 23 and 24: Match - Project DK-1001-01 23
Page 25 and 26: MPC Validation: the mondoBIOTECH Co
Page 27 and 28: Set up of new projects PROJECT SET
Page 29: Intellectual Property Strategy & Cu
Page 33 and 34: mondoBIOTECH’s IP Strategy: Two I
Page 35 and 36: Orphan Drug Designations 10 Granted
Page 37 and 38: Why Peptides Peptides characteristi
Page 40 and 41: Diversifying the Risk in Drug Disco
Page 42 and 43: Current Pipeline DasKloster 1000-01
Page 46: Scientific Snapshot Information: DK
Page 49 and 50: Scientific Snapshot Information: DK
Page 51 and 52: Products licensed DasKloster 1001-0
Page 53 and 54: Licensed Products • Aviptadil pla
Page 55: mondoBIOTECH holding AG DasKloster

Mondobiotech Holding AG Company presentation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?